Literature DB >> 24064685

Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause.

Corrine K Welt1, Enrico Carmina.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is diagnosed during the reproductive years when women present with 2 of 3 of the following criteria: 1) irregular menstrual cycles or anovulation, 2) hyperandrogenism, and 3) PCO morphology. However, there is evidence that PCOS can be identified from early infancy to puberty based on predisposing environmental influences. There is also increasing information about the PCOS phenotype after menopause. The goal of this review is to summarize current knowledge about the appearance of PCOS at different life stages and the influence of reproductive maturation and senescence on the PCOS phenotype. EVIDENCE: PubMed, the bibliography from the Evidence-Based PCOS Workshop, and the reference lists from identified manuscripts were reviewed. EVIDENCE SYNTHESIS: The current data suggest that daughters of women with PCOS have a greater follicle complement and mild metabolic abnormalities from infancy. PCOS is often diagnosed in puberty with the onset of hyperandrogenism and may be preceded by premature pubarche. During the reproductive years, there is a gradual decrease in the severity of the cardinal features of PCOS. Menopausal data suggest that the majority of women who had PCOS during their reproductive years continue to manifest cardiovascular risk factors. However, the majority do not present an increased risk for cardiovascular morbidity and mortality, perhaps because women with no history of PCOS may catch up after menopause.
CONCLUSION: The current data provide a comprehensive starting point to understand the phenotype of PCOS across the lifespan. However, limitations such as a bias of ascertainment in childhood, age-based changes during reproductive life, and the small numbers studied during menopause point to the need for additional longitudinal studies to expand the current knowledge.

Entities:  

Mesh:

Year:  2013        PMID: 24064685      PMCID: PMC3849665          DOI: 10.1210/jc.2013-2375

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  81 in total

1.  Age-related changes in ovarian volume, antral follicle counts and basal FSH in women with normal reproductive health.

Authors:  Ahmet Erdem; Mehmet Erdem; Kutay Biberoglu; Ozkan Hayit; Murat Arslan; Rifat Gursoy
Journal:  J Reprod Med       Date:  2002-10       Impact factor: 0.142

2.  Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls.

Authors:  Christopher R McCartney; Susan K Blank; Kathleen A Prendergast; Sandhya Chhabra; Christine A Eagleson; Kristin D Helm; Richard Yoo; R Jeffrey Chang; Carol M Foster; Sonia Caprio; John C Marshall
Journal:  J Clin Endocrinol Metab       Date:  2006-11-21       Impact factor: 5.958

3.  Polycystic ovaries in pre and post-menopausal women.

Authors:  M A Birdsall; C M Farquhar
Journal:  Clin Endocrinol (Oxf)       Date:  1996-03       Impact factor: 3.478

4.  Is polycystic ovary syndrome an exception for reproductive aging?

Authors:  Fahimeh Ramezani Tehrani; Masoud Solaymani-Dodaran; Mehdi Hedayati; Fereidoun Azizi
Journal:  Hum Reprod       Date:  2010-04-30       Impact factor: 6.918

5.  Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.

Authors:  Thomas M Barber; John A H Wass; Mark I McCarthy; Stephen Franks
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04       Impact factor: 3.478

6.  Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.

Authors:  Didier Dewailly; Pascal Pigny; Benoît Soudan; Sophie Catteau-Jonard; Christine Decanter; Edouard Poncelet; Alain Duhamel
Journal:  J Clin Endocrinol Metab       Date:  2010-07-07       Impact factor: 5.958

7.  Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility.

Authors:  G J Scheffer; F J Broekmans; M Dorland; J D Habbema; C W Looman; E R te Velde
Journal:  Fertil Steril       Date:  1999-11       Impact factor: 7.329

8.  Effects of birth weight on anti-mullerian hormone serum concentrations in infant girls.

Authors:  Teresa Sir-Petermann; Lorena Márquez; Michael Cárcamo; Catalina Hitschfeld; Ethel Codner; Manuel Maliqueo; Bárbara Echiburú; Pablo Aranda; Nicolás Crisosto; Fernando Cassorla
Journal:  J Clin Endocrinol Metab       Date:  2009-11-24       Impact factor: 5.958

9.  Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.

Authors:  Johanna Puurunen; Terhi Piltonen; Päivi Jaakkola; Aimo Ruokonen; Laure Morin-Papunen; Juha S Tapanainen
Journal:  J Clin Endocrinol Metab       Date:  2009-03-24       Impact factor: 5.958

10.  Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.

Authors:  E Dahlgren; S Johansson; G Lindstedt; F Knutsson; A Odén; P O Janson; L A Mattson; N Crona; P A Lundberg
Journal:  Fertil Steril       Date:  1992-03       Impact factor: 7.329

View more
  28 in total

Review 1.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

Review 2.  Androgens and Blood Pressure Control: Sex Differences and Mechanisms.

Authors:  Jane F Reckelhoff
Journal:  Mayo Clin Proc       Date:  2019-01-31       Impact factor: 7.616

3.  Polycystic ovary morphology: age-based ultrasound criteria.

Authors:  Hyun-Jun Kim; Judith M Adams; Jens A Gudmundsson; Gudmundur Arason; Cindy T Pau; Corrine K Welt
Journal:  Fertil Steril       Date:  2017-08-12       Impact factor: 7.329

4.  Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.

Authors:  Danalea V Skarra; Angelina Hernández-Carretero; Alissa J Rivera; Arya R Anvar; Varykina G Thackray
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

Review 5.  Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome.

Authors:  Márcia Marly Winck Yamamoto; Sebastião Freitas de Medeiros
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 6.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

7.  Osteosarcopenia in Reproductive-Aged Women with Polycystic Ovary Syndrome: A Multicenter Case-Control Study.

Authors:  Maryam Kazemi; Brittany Y Jarrett; Stephen A Parry; Anna E Thalacker-Mercer; Kathleen M Hoeger; Steven D Spandorfer; Marla E Lujan
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 8.  The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis.

Authors:  Hannah E Young; Wendy E Ward
Journal:  Reprod Sci       Date:  2020-09-10       Impact factor: 3.060

9.  Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition.

Authors:  Alex J Polotsky; Amanda A Allshouse; Sybil L Crawford; Sioban D Harlow; Naila Khalil; Rasa Kazlauskaite; Nanette Santoro; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

Review 10.  Ovarian Physiology and GWAS: Biobanks, Biology, and Beyond.

Authors:  Triin Laisk-Podar; Cecilia M Lindgren; Maire Peters; Juha S Tapanainen; Cornelis B Lambalk; Andres Salumets; Reedik Mägi
Journal:  Trends Endocrinol Metab       Date:  2016-05-21       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.